Concepedia

Tolvaptan Therapy

Tolvaptan Therapy is a pharmacological treatment involving the selective vasopressin V2 receptor antagonist tolvaptan, distinguished by its specific mechanism of reducing cyst growth and slowing renal function decline in autosomal dominant polycystic kidney disease.

310

Publications

19K

Citations

1.7K

Authors

622

Institutions

Publications per year

2017–2026

139

Parents

Publications

310

Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure<SUBTITLE>The EVEREST Outcome Trial</SUBTITLE>

Marvin A. Konstam · JAMA · 2007 · 1.6K citations

, , +16

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · New England Journal of Medicine · 2012 · 1.6K citations · Full text

, , +14

Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia

Robert W. Schrier, Mihai Gheorghiade, Tomás Berl et al. · New England Journal of Medicine · 2006 · 1.2K citations · Full text

, , +17

Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure&lt;SUBTITLE&gt;The EVEREST Clinical Status Trials&lt;/SUBTITLE&gt;

Mihai Gheorghiade · JAMA · 2007 · 840 citations

, , +17

Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure&lt;SUBTITLE&gt;A Randomized Controlled Trial&lt;/SUBTITLE&gt;

Mihai Gheorghiade · JAMA · 2004 · 648 citations

, , +16

1–5 of 310

Authors

1.7K

  1. FS
    Frank S. Czerwiec

    Otsuka (United States), United States

    31 publications · 6.5K citations

    27

    h-index

  2. JO
    John Ouyang

    Otsuka (United States), United States

    35 publications · 5.4K citations

    27

    h-index

  3. VE
    Vicente E. Torres

    Mayo Clinic, United States

    25 publications · 4K citations

    23

    h-index

  4. RT
    Ron T. Gansevoort

    University Medical Center Groningen, Netherlands

    20 publications · 3.4K citations

    20

    h-index

  5. AB
    Arlene B. Chapman

    Mayo Clinic, United States

    18 publications · 3.4K citations

    18

    h-index

1–5 of 1.7K

Institutions

622

  1. Otsuka (United States)

    Princeton, United States

    39 h-index

    211 publications

    23.6K citations

  2. Pharmaceutical Product Development (United States)

    Wilmington, United States

    33 h-index

    158 publications

    18.6K citations

  3. Mayo Clinic

    Rochester, United States

    24 h-index

    55 publications

    6.4K citations

  4. Otsuka (Japan)

    Tokyo, Japan

    23 h-index

    137 publications

    4.9K citations

  5. Tufts Medical Center

    Boston, United States

    22 h-index

    32 publications

    6.5K citations

  6. University Medical Center Groningen

    Groningen, The Netherlands

    20 h-index

    68 publications

    11.8K citations

  7. Otsuka Pharmaceutical (Spain)

    Barcelona, Spain

    18 h-index

    60 publications

    4.5K citations

  8. University of Groningen

    Groningen, The Netherlands

    17 h-index

    52 publications

    4.8K citations

1–8 of 622

Venues

  1. International Heart Journal

    14 publications · 242 citations

    12

    h-index

  2. Clinical Journal of the American Society of Nephrology

    CJASN · 13 publications · 819 citations

    12

    h-index

  3. Circulation Journal

    12 publications · 630 citations

    12

    h-index

  4. Clinical and Experimental Nephrology

    12 publications · 262 citations

    11

    h-index

  5. Hepatology Research

    10 publications · 427 citations

    10

    h-index

1–5